Innovaderm’s Leading Expertise in Dermatology is to be Featured at the Society for Investigative Dermatology’s (SID) Pfizer Late-Breaking Session

Innovaderm’s expertise will be highlighted once more during a late-breaking session at the 2024 Society for Investigative Dermatology (SID) annual meeting in Dallas, Texas.

Results of this Pfizer-sponsored trial will be presented at the annual event, on Friday, May 17, 2024.

C3941005 study title: A phase 2b, randomized, double blind, vehicle controlled, parallel group study to assess the efficacy, safety, tolerability and pharmacokinetics of multiple dose levels of PF-07038124 ointment for 12 weeks in participants 12 years and older and with mild-to-moderate atopic dermatitis or mild-to-severe plaque psoriasis

Innovaderm’s clinical site was an active participant in this study.

Innovaderm is immensely proud of its role in improving the lives of patients with skin diseases.

Click here for more information on this dermatology trial.


L’expertise d’Innovaderm sera une fois de plus mise en valeur lors de la réunion annuelle du SID à Dallas, au Texas.

Les résultats de l’étude C3941005 de Pfizer seront présentés lors de l’événement, le vendredi 17 mai 2024.

Le site clinique d’Innovaderm a participé activement à cette étude.

Innovaderm est fière de son rôle dans l’amélioration de la vie des patients atteints de maladies de la peau.

Suivez ce lien pour plus d’information sur cette étude clinique.

Contact us


Get notified to have the latest trends and be at the forefront of dermatology clinical research and innovation.

Newsletter subscription resources

*By subscribing to our newsletter, you acknowledge and agree to the terms of our privacy policy.